SCHEMBL3016316

SCHEMBL3016316

CC(C)c1cc(C(C)C)c(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)cc4Cl)cs3)CC2)c(C(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.37
GAA P10253 1/20 0.34
EPHX2 P34913 1/20 0.34
MAPT P10636 3/20 0.33
AR P10275 1/20 0.33
OGA O60502 2/20 0.33
PTGER1 P34995 2/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
MC4R P32245 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
GRM2 Q14416 1/20 0.32
GRM3 Q14832 1/20 0.32
RAB9A P51151 1/20 0.32
EGFR P00533 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013690 0.90 FABP4 (0.37) FABP4MAPTOGAPTGER1PSEN1
SCHEMBL3019281 0.88 HRH3 (0.35) FABP4GAAEPHX2MAPTOGA
SCHEMBL3004517 0.87 LMNA (0.37) FABP4EPHX2MAPTAROGA
SCHEMBL3005463 0.87 FABP4 (0.43) FABP4GAAEPHX2MAPTAR
SCHEMBL3009892 0.86 CACNA1G (0.37) FABP4GAAMAPTAROGA
SCHEMBL3018020 0.85 ALDH1A1 (0.35) FABP4OGAHRH3SMN1; SMN2RAB9A
SCHEMBL3012900 0.85 DNM1L (0.37) OGAHRH3LMNAMAPK1ALDH1A1
SCHEMBL3018214 0.85 CACNA1G (0.37) FABP4OGAHRH3SMN1; SMN2RAB9A
SCHEMBL3021020 0.84 AR (0.34) FABP4MAPTAROGAHRH3
SCHEMBL3014519 0.84 AR (0.52) FABP4MAPTARSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA FABP4 3254/4885GAA 110/4885EPHX2 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.